# 3M Co: financial statements, quarterly MMM · NYSE · CIK 66740 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mmm.md) · [Financials](/companies/mmm/financials.md) · [Filings](/companies/mmm/filings.md) · [Insiders](/companies/mmm/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mmm/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6,002](/filings/0000066740-25-000006.md) | [6,016](/filings/0000066740-25-000039.md) | [6,255](/filings/0000066740-25-000063.md) | [6,294](/filings/0000066740-25-000089.md) | [6,010](/filings/0000066740-25-000006.md) | [5,954](/filings/0000066740-26-000175.md) | [6,344](/filings/0000066740-26-000246.md) | [6,517](/filings/0000066740-26-000311.md) | [6,133 d](/filings/0000066740-26-000014.md) | [6,030](/filings/0000066740-26-000175.md) | [6,500](/filings/0000066740-26-000246.md) | [6,584](/filings/0000066740-26-000311.md) | | Cost of revenue | $m | [3,795](/filings/0000066740-25-000006.md) | [3,485](/filings/0000066740-25-000039.md) | [3,571](/filings/0000066740-25-000063.md) | [3,647](/filings/0000066740-25-000089.md) | [3,744](/filings/0000066740-25-000006.md) | [3,478](/filings/0000066740-26-000175.md) | [3,646](/filings/0000066740-26-000246.md) | [3,792](/filings/0000066740-26-000311.md) | [4,075 d](/filings/0000066740-26-000014.md) | [3,574](/filings/0000066740-26-000175.md) | [3,817](/filings/0000066740-26-000246.md) | [3,801](/filings/0000066740-26-000311.md) | | Selling, general and administrative | $m | [1,016 d](/filings/0000066740-26-000014.md) | [1,128](/filings/0000066740-25-000039.md) | [1,132](/filings/0000066740-25-000063.md) | [1,062](/filings/0000066740-25-000089.md) | [899 d](/filings/0000066740-26-000014.md) | [945](/filings/0000066740-26-000175.md) | [1,267](/filings/0000066740-26-000246.md) | [820](/filings/0000066740-26-000311.md) | [965 d](/filings/0000066740-26-000014.md) | [744](/filings/0000066740-26-000175.md) | [1,061](/filings/0000066740-26-000246.md) | [921](/filings/0000066740-26-000311.md) | | Operating income | $m | [899 d](/filings/0000066740-26-000014.md) | [1,149](/filings/0000066740-25-000039.md) | [1,272](/filings/0000066740-25-000063.md) | [1,316](/filings/0000066740-25-000089.md) | [1,085 d](/filings/0000066740-26-000014.md) | [1,246](/filings/0000066740-26-000175.md) | [1,140](/filings/0000066740-26-000246.md) | [1,447](/filings/0000066740-26-000311.md) | [796 d](/filings/0000066740-26-000014.md) | [1,397](/filings/0000066740-26-000175.md) | [984](/filings/0000066740-26-000246.md) | [1,558](/filings/0000066740-26-000311.md) | | Interest expense | $m | [371 d](/filings/0000066740-24-000016.md) | [385](/filings/0000066740-24-000053.md) | [322](/filings/0000066740-24-000080.md) | [276](/filings/0000066740-25-000089.md) | [252 d](/filings/0000066740-26-000014.md) | [255](/filings/0000066740-26-000175.md) | [237](/filings/0000066740-26-000246.md) | [232](/filings/0000066740-26-000311.md) | [222 d](/filings/0000066740-26-000014.md) | [214](/filings/0000066740-26-000175.md) | [202](/filings/0000066740-26-000246.md) | [217](/filings/0000066740-26-000311.md) | | Income tax | $m | [26.0 d](/filings/0000066740-26-000014.md) | [220](/filings/0000066740-25-000039.md) | [203](/filings/0000066740-25-000063.md) | [348](/filings/0000066740-25-000089.md) | [33.0 d](/filings/0000066740-26-000014.md) | [265](/filings/0000066740-26-000175.md) | [245](/filings/0000066740-26-000246.md) | [308](/filings/0000066740-26-000311.md) | [185 d](/filings/0000066740-26-000014.md) | [221](/filings/0000066740-26-000175.md) | [183](/filings/0000066740-26-000246.md) | [261](/filings/0000066740-26-000311.md) | | Net income | $m | [945](/filings/0000066740-25-000006.md) | [928](/filings/0000066740-25-000039.md) | [1,145](/filings/0000066740-25-000063.md) | [1,372](/filings/0000066740-25-000089.md) | [728](/filings/0000066740-25-000006.md) | [1,116](/filings/0000066740-26-000175.md) | [723](/filings/0000066740-26-000246.md) | [834](/filings/0000066740-26-000311.md) | [577 d](/filings/0000066740-26-000014.md) | [653](/filings/0000066740-26-000175.md) | [933](/filings/0000066740-26-000246.md) | [1,373](/filings/0000066740-26-000311.md) | | Diluted EPS | $ per share | [1.70](/filings/0000066740-25-000006.md) | [1.67](/filings/0000066740-25-000039.md) | [2.07](/filings/0000066740-25-000063.md) | [2.48](/filings/0000066740-25-000089.md) | [1.33](/filings/0000066740-25-000006.md) | [2.04](/filings/0000066740-26-000175.md) | [1.34](/filings/0000066740-26-000246.md) | [1.55](/filings/0000066740-26-000311.md) | not reported | [1.23](/filings/0000066740-26-000175.md) | [1.78](/filings/0000066740-26-000246.md) | [2.63](/filings/0000066740-26-000311.md) | | Basic EPS | $ per share | [1.70](/filings/0000066740-25-000006.md) | [1.67](/filings/0000066740-25-000039.md) | [2.07](/filings/0000066740-25-000063.md) | [2.49](/filings/0000066740-25-000089.md) | [1.34](/filings/0000066740-25-000006.md) | [2.05](/filings/0000066740-26-000175.md) | [1.35](/filings/0000066740-26-000246.md) | [1.56](/filings/0000066740-26-000311.md) | not reported | [1.23](/filings/0000066740-26-000175.md) | [1.79](/filings/0000066740-26-000246.md) | [2.65](/filings/0000066740-26-000311.md) | - Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current assets | $bn | [16.4](/filings/0000066740-25-000006.md) | [21.6](/filings/0000066740-24-000053.md) | [19.5](/filings/0000066740-24-000080.md) | [16.3](/filings/0000066740-24-000101.md) | [15.9](/filings/0000066740-26-000014.md) | [15.7](/filings/0000066740-25-000039.md) | [13.4](/filings/0000066740-25-000063.md) | [16.1](/filings/0000066740-25-000089.md) | [16.4](/filings/0000066740-26-000311.md) | [14.4](/filings/0000066740-26-000175.md) | [14.1](/filings/0000066740-26-000246.md) | [16.7](/filings/0000066740-26-000311.md) | | Total assets | $bn | [50.6](/filings/0000066740-25-000006.md) | [55.2](/filings/0000066740-24-000053.md) | [43.4](/filings/0000066740-24-000080.md) | [40.9](/filings/0000066740-24-000101.md) | [39.9](/filings/0000066740-26-000014.md) | [40.0](/filings/0000066740-25-000039.md) | [38.0](/filings/0000066740-25-000063.md) | [37.6](/filings/0000066740-25-000089.md) | [37.7](/filings/0000066740-26-000311.md) | [35.4](/filings/0000066740-26-000175.md) | [34.9](/filings/0000066740-26-000246.md) | [39.5](/filings/0000066740-26-000311.md) | | Current liabilities | $bn | [15.3](/filings/0000066740-25-000006.md) | [13.2](/filings/0000066740-24-000053.md) | [14.3](/filings/0000066740-24-000080.md) | [11.4](/filings/0000066740-24-000101.md) | [11.3](/filings/0000066740-26-000014.md) | [9.5](/filings/0000066740-25-000039.md) | [7.8](/filings/0000066740-25-000063.md) | [8.7](/filings/0000066740-25-000089.md) | [9.6](/filings/0000066740-26-000311.md) | [9.0](/filings/0000066740-26-000175.md) | [11.4](/filings/0000066740-26-000246.md) | [11.9](/filings/0000066740-26-000311.md) | | Total liabilities | $bn | [45.7](/filings/0000066740-25-000006.md) | [50.3](/filings/0000066740-24-000053.md) | [39.4](/filings/0000066740-24-000080.md) | [36.2](/filings/0000066740-24-000101.md) | [36.0](/filings/0000066740-26-000014.md) | [35.4](/filings/0000066740-25-000039.md) | [33.6](/filings/0000066740-25-000063.md) | [32.9](/filings/0000066740-25-000089.md) | [33.0](/filings/0000066740-26-000311.md) | [32.1](/filings/0000066740-26-000175.md) | [31.9](/filings/0000066740-26-000246.md) | [34.4](/filings/0000066740-26-000311.md) | | Long-term debt | $bn | [13.1](/filings/0000066740-25-000006.md) | [20.6](/filings/0000066740-24-000053.md) | [11.8](/filings/0000066740-24-000080.md) | [11.3](/filings/0000066740-24-000101.md) | [11.1](/filings/0000066740-26-000014.md) | [12.3](/filings/0000066740-25-000039.md) | [12.5](/filings/0000066740-25-000063.md) | [11.9](/filings/0000066740-25-000089.md) | [10.9](/filings/0000066740-26-000311.md) | [10.9](/filings/0000066740-26-000175.md) | [10.9](/filings/0000066740-26-000246.md) | [12.6](/filings/0000066740-26-000311.md) | | Current portion of debt | $bn | [1.2](/filings/0000066740-25-000006.md) | [0.8](/filings/0000066740-24-000053.md) | [1.3](/filings/0000066740-24-000080.md) | [1.9](/filings/0000066740-24-000101.md) | [1.9](/filings/0000066740-26-000014.md) | [1.2](/filings/0000066740-25-000039.md) | [0.7](/filings/0000066740-25-000063.md) | [0.7](/filings/0000066740-25-000089.md) | [1.7](/filings/0000066740-26-000014.md) | [1.7](/filings/0000066740-26-000175.md) | [1.6](/filings/0000066740-26-000246.md) | [2.4](/filings/0000066740-26-000311.md) | | Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $bn | [4.8](/filings/0000066740-25-000006.md) | [4.9](/filings/0000066740-24-000053.md) | [3.9](/filings/0000066740-24-000080.md) | [4.6](/filings/0000066740-24-000101.md) | [3.8](/filings/0000066740-26-000014.md) | [4.5](/filings/0000066740-25-000039.md) | [4.3](/filings/0000066740-25-000063.md) | [4.6](/filings/0000066740-25-000089.md) | [4.7](/filings/0000066740-26-000311.md) | [3.3](/filings/0000066740-26-000175.md) | [3.0](/filings/0000066740-26-000246.md) | [4.1](/filings/0000066740-26-000311.md) | - Cash and equivalents: not reported - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent - Short-term borrowings: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [1,986 d](/filings/0000066740-26-000014.md) | [767](/filings/0000066740-25-000039.md) | [1,021 d](/filings/0000066740-25-000063.md) | [(1,787) d](/filings/0000066740-25-000089.md) | [1,818 d](/filings/0000066740-26-000014.md) | [(79.0)](/filings/0000066740-26-000175.md) | [(954) d](/filings/0000066740-26-000246.md) | [1,756 d](/filings/0000066740-26-000311.md) | [1,583 d](/filings/0000066740-26-000014.md) | [574](/filings/0000066740-26-000175.md) | [986 d](/filings/0000066740-26-000246.md) | [486 d](/filings/0000066740-26-000311.md) | | Capital expenditure | $m | [358 d](/filings/0000066740-26-000014.md) | [375](/filings/0000066740-25-000039.md) | [269 d](/filings/0000066740-25-000063.md) | [246 d](/filings/0000066740-25-000089.md) | [291 d](/filings/0000066740-26-000014.md) | [236](/filings/0000066740-26-000175.md) | [208 d](/filings/0000066740-26-000246.md) | [218 d](/filings/0000066740-26-000311.md) | [248 d](/filings/0000066740-26-000014.md) | [225](/filings/0000066740-26-000175.md) | [223 d](/filings/0000066740-26-000246.md) | [256 d](/filings/0000066740-26-000311.md) | | Dividends paid | $m | [828 d](/filings/0000066740-26-000014.md) | [835](/filings/0000066740-25-000039.md) | [386 d](/filings/0000066740-25-000063.md) | [383 d](/filings/0000066740-25-000089.md) | [378 d](/filings/0000066740-26-000014.md) | [396](/filings/0000066740-26-000175.md) | [390 d](/filings/0000066740-26-000246.md) | [389 d](/filings/0000066740-26-000311.md) | [387 d](/filings/0000066740-26-000014.md) | [412](/filings/0000066740-26-000175.md) | [401 d](/filings/0000066740-26-000246.md) | [403 d](/filings/0000066740-26-000311.md) | | Share repurchases | $m | [2.0 d](/filings/0000066740-26-000014.md) | [21.0](/filings/0000066740-25-000039.md) | [400 d](/filings/0000066740-25-000063.md) | [675 d](/filings/0000066740-25-000089.md) | [705 d](/filings/0000066740-26-000014.md) | [1,274](/filings/0000066740-26-000175.md) | [953 d](/filings/0000066740-26-000246.md) | [472 d](/filings/0000066740-26-000311.md) | [552 d](/filings/0000066740-26-000014.md) | [1,999](/filings/0000066740-26-000175.md) | [994 d](/filings/0000066740-26-000246.md) | [232 d](/filings/0000066740-26-000311.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [553](/filings/0000066740-24-000053.md) | [554](/filings/0000066740-24-000080.md) | [554](/filings/0000066740-24-000101.md) | [556](/filings/0000066740-25-000039.md) | [555](/filings/0000066740-25-000063.md) | [553](/filings/0000066740-25-000089.md) | [548](/filings/0000066740-26-000175.md) | [541](/filings/0000066740-26-000246.md) | [538](/filings/0000066740-26-000311.md) | [533](/filings/0000066740-26-000175.md) | [522](/filings/0000066740-26-000246.md) | [523](/filings/0000066740-26-000311.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 516,729,574 at 2026-09-30, from the cover of the [10-Q filed 2026-10-20](/filings/0000066740-26-000311.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.